PLSE PULSE BIOSCIENCES, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1625101 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,637.2%
TTM net income YoY-12.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin26.8%
Operating margin-5,821.1%
Net margin-5,603.9%
FCF margin-4,263.9%
EBITDA margin-5,796.8%
Returns
ROE-60.6%
ROA-54.0%
ROIC (approx.)-95.2%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets8.9%
Debt / equity0.00x
Current ratio14.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue24.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $395,000 | $434,000 | $401,000 | $264,000 | $86,000 | $0 | $0 | $0 |
| Cost of revenue | $191,000 | $273,000 | $370,000 | $260,000 | $279,000 | $0 | $0 | $0 |
| Gross profit | $204,000 | $161,000 | $31,000 | $4,000 | -$193,000 | $0 | $0 | $0 |
| R&D expense | $16.85M | $16.98M | $12.59M | $10.93M | $11.39M | $12.09M | $10.31M | $10.66M |
| SG&A expense | $7.65M | $8.46M | $6.59M | $7.33M | $8.78M | $8.19M | $7.73M | $9.60M |
| Operating income | -$24.29M | -$25.27M | -$19.15M | -$18.25M | -$20.37M | -$20.27M | -$18.04M | -$20.26M |
| Pretax income | — | — | — | — | — | -$19.17M | -$16.80M | -$19.39M |
| Income tax | — | — | — | — | — | $0 | $0 | $0 |
| Net income | -$23.05M | -$24.66M | -$18.58M | -$17.43M | -$19.39M | -$19.17M | -$16.80M | -$19.39M |
| EBITDA | -$24.20M | -$25.18M | -$19.06M | -$18.16M | -$20.27M | -$20.18M | -$17.93M | -$20.14M |
| EPS (basic) | -0.32 | -0.36 | -0.27 | — | -0.29 | -0.28 | -0.25 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $36.73M | $101.62M | $68.32M | $80.73M | $95.21M | $106.35M | $119.28M | $118.04M |
| Receivables | $297,000 | $122,000 | $157,000 | $274,000 | $15,000 | — | — | $0 |
| Inventory | $232,000 | $236,000 | $206,000 | $136,000 | $57,000 | $51,000 | $30,000 | $0 |
| Current assets | $192.21M | $105.70M | $71.13M | $83.42M | $97.16M | $108.16M | $120.91M | $119.45M |
| PP&E, net | $1.07M | $1.06M | $1.02M | $1.05M | $1.05M | $1.11M | $1.06M | $1.16M |
| Goodwill | $2.79M | $2.79M | $2.79M | $2.79M | $2.79M | $2.79M | $2.79M | $2.79M |
| Intangibles | $55,000 | $222,000 | $408,000 | $575,000 | $741,000 | $907,000 | $1.05M | $1.22M |
| Total assets | $201.58M | $115.56M | $81.62M | $94.54M | $108.77M | $120.25M | $133.38M | $132.46M |
| Current liabilities | $13.39M | $10.98M | $9.80M | $7.92M | $9.70M | $8.98M | $7.76M | $10.05M |
| Total liabilities | $18.01M | $16.06M | $15.32M | $13.88M | $16.07M | $15.76M | $14.93M | $17.60M |
| Shareholders' equity | $183.57M | $99.50M | $66.30M | $80.66M | $92.69M | $104.49M | $118.45M | $114.86M |
| Shares outstanding | 73.31M | 70.80M | 68.23M | 67.84M | 67.74M | 67.28M | 67.27M | 65.93M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.27M | -$18.71M | -$14.60M | -$14.76M | -$13.04M | -$12.81M | -$13.52M | -$9.14M |
| Capital expenditure | $142,000 | $90,000 | $33,000 | $105,000 | $62,000 | $103,000 | $45,000 | $53,000 |
| Free cash flow | -$15.41M | -$18.80M | -$14.63M | -$14.86M | -$13.10M | -$12.91M | -$13.57M | -$9.20M |
| Investing cash flow | -$152.49M | -$90,000 | -$33,000 | -$105,000 | -$62,000 | -$123,000 | -$45,000 | -$53,000 |
| Financing cash flow | $102.87M | $52.10M | $2.21M | $381,000 | $1.97M | $0 | $14.81M | $48.20M |
| Depreciation & amortization | $94,000 | $88,000 | $88,000 | $93,000 | $100,000 | $100,000 | $117,000 | $121,000 |
| Stock-based compensation | $5.31M | $4.97M | $1.91M | $4.97M | $5.62M | $5.19M | $5.68M | $6.79M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.